All studies point to MANF. And these are only the
Post# of 30028
(Total Views: 594)
Posted On: 01/18/2018 11:22:06 PM
All studies point to MANF. And these are only the ones we can find and read. Imagine all the other ones out there or haven't been peered review yet.
This quote from Dr. Rubinfeld is from 5 years ago. How did he know? There are now 5 years of studies to valid what Dr. Rubinfeld and Dr. Commissiong knew years ago. "The fundamental scientific premise of reducing protein misfolding is basic, yet very profound."
I figured it would take 5 years to get to the point of validation. There are so many institution now doing research on MANF worldwide. Saves the company $100's of millions.
Will be interesting to see the IPO on MANF.
NOVEMBER 06, 2012
"I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."
https://www.amarantus.com/news/press-releases...-dr-joseph
This quote from Dr. Rubinfeld is from 5 years ago. How did he know? There are now 5 years of studies to valid what Dr. Rubinfeld and Dr. Commissiong knew years ago. "The fundamental scientific premise of reducing protein misfolding is basic, yet very profound."
I figured it would take 5 years to get to the point of validation. There are so many institution now doing research on MANF worldwide. Saves the company $100's of millions.
Will be interesting to see the IPO on MANF.
NOVEMBER 06, 2012
"I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen. The fundamental scientific premise of reducing protein misfolding is basic, yet very profound. The data, while early, demonstrates very clearly at the cellular level and in animals that MANF reduces apoptosis, improves cellular function, and restores behavioural deficits in a number of disease models, including Parkinson's, Stroke, Myocardial Infarction and Traumatic Brain Injury. These are all indications with very large markets and clear unmet medical need. I believe that if we are able to further de-risk MANF with positive toxicology studies and early clinical data, the Company's new orphan drug strategy could get MANF to market rather expeditiously. MANF has the commercial potential to become a blockbuster drug."
https://www.amarantus.com/news/press-releases...-dr-joseph
(9)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼